Role of pramipexole in the management of Parkinsons disease

Angelo Antonini, Paolo Barone, Roberto Ceravolo, Giovanni Fabbrini, Michele Tinazzi, Giovanni Abbruzzese

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and symptoms of idiopathic Parkinsons disease and for the treatment of moderate-to-severe primary restless legs syndrome. A new extended-release formulation of pramipexole has now also been launched in Europe and the US to improve ease of use, compliance and provide a more continuous therapeutic effect over 24 hours. Before initiating any treatment, the benefit-risk ratio to the individual patient must be considered. For pramipexole in the treatment of Parkinsons disease, this means taking into account the available evidence regarding its symptomatic efficacy, effect on delaying long-term levodopa-related motor complications, beneficial effect on non-motor symptoms such as depression, and its safety and tolerability profile. Studies have shown that pramipexole is effective as monotherapy in early Parkinsons disease and as adjunctive therapy in advanced disease. Trials further suggest that the benefits of pramipexole may extend beyond the relief of motor symptoms (akinesia, rigidity and tremor at rest) to the amelioration of depressive symptoms in Parkinsons disease. Pramipexole is generally well tolerated; however, compared with levodopa treatment, pramipexole is associated with a higher rate of some dopaminergic adverse effects.

Original languageEnglish
Pages (from-to)829-841
Number of pages13
JournalCNS Drugs
Volume24
Issue number10
DOIs
Publication statusPublished - 2010

Fingerprint

Parkinson Disease
Levodopa
Therapeutics
Depression
Restless Legs Syndrome
Dopamine Agents
Dopamine Agonists
Tremor
Therapeutic Uses
pramipexole
Compliance
Signs and Symptoms
Odds Ratio
Safety

Keywords

  • Parkinsons-disease, treatment
  • Pramipexole, pharmacokinetics
  • Pramipexole, therapeutic use

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Clinical Neurology

Cite this

Antonini, A., Barone, P., Ceravolo, R., Fabbrini, G., Tinazzi, M., & Abbruzzese, G. (2010). Role of pramipexole in the management of Parkinsons disease. CNS Drugs, 24(10), 829-841. https://doi.org/10.2165/11585090-000000000-00000

Role of pramipexole in the management of Parkinsons disease. / Antonini, Angelo; Barone, Paolo; Ceravolo, Roberto; Fabbrini, Giovanni; Tinazzi, Michele; Abbruzzese, Giovanni.

In: CNS Drugs, Vol. 24, No. 10, 2010, p. 829-841.

Research output: Contribution to journalArticle

Antonini, A, Barone, P, Ceravolo, R, Fabbrini, G, Tinazzi, M & Abbruzzese, G 2010, 'Role of pramipexole in the management of Parkinsons disease', CNS Drugs, vol. 24, no. 10, pp. 829-841. https://doi.org/10.2165/11585090-000000000-00000
Antonini, Angelo ; Barone, Paolo ; Ceravolo, Roberto ; Fabbrini, Giovanni ; Tinazzi, Michele ; Abbruzzese, Giovanni. / Role of pramipexole in the management of Parkinsons disease. In: CNS Drugs. 2010 ; Vol. 24, No. 10. pp. 829-841.
@article{a6cf0c72e8ae44c48d18dc86e68c36d0,
title = "Role of pramipexole in the management of Parkinsons disease",
abstract = "The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and symptoms of idiopathic Parkinsons disease and for the treatment of moderate-to-severe primary restless legs syndrome. A new extended-release formulation of pramipexole has now also been launched in Europe and the US to improve ease of use, compliance and provide a more continuous therapeutic effect over 24 hours. Before initiating any treatment, the benefit-risk ratio to the individual patient must be considered. For pramipexole in the treatment of Parkinsons disease, this means taking into account the available evidence regarding its symptomatic efficacy, effect on delaying long-term levodopa-related motor complications, beneficial effect on non-motor symptoms such as depression, and its safety and tolerability profile. Studies have shown that pramipexole is effective as monotherapy in early Parkinsons disease and as adjunctive therapy in advanced disease. Trials further suggest that the benefits of pramipexole may extend beyond the relief of motor symptoms (akinesia, rigidity and tremor at rest) to the amelioration of depressive symptoms in Parkinsons disease. Pramipexole is generally well tolerated; however, compared with levodopa treatment, pramipexole is associated with a higher rate of some dopaminergic adverse effects.",
keywords = "Parkinsons-disease, treatment, Pramipexole, pharmacokinetics, Pramipexole, therapeutic use",
author = "Angelo Antonini and Paolo Barone and Roberto Ceravolo and Giovanni Fabbrini and Michele Tinazzi and Giovanni Abbruzzese",
year = "2010",
doi = "10.2165/11585090-000000000-00000",
language = "English",
volume = "24",
pages = "829--841",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "10",

}

TY - JOUR

T1 - Role of pramipexole in the management of Parkinsons disease

AU - Antonini, Angelo

AU - Barone, Paolo

AU - Ceravolo, Roberto

AU - Fabbrini, Giovanni

AU - Tinazzi, Michele

AU - Abbruzzese, Giovanni

PY - 2010

Y1 - 2010

N2 - The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and symptoms of idiopathic Parkinsons disease and for the treatment of moderate-to-severe primary restless legs syndrome. A new extended-release formulation of pramipexole has now also been launched in Europe and the US to improve ease of use, compliance and provide a more continuous therapeutic effect over 24 hours. Before initiating any treatment, the benefit-risk ratio to the individual patient must be considered. For pramipexole in the treatment of Parkinsons disease, this means taking into account the available evidence regarding its symptomatic efficacy, effect on delaying long-term levodopa-related motor complications, beneficial effect on non-motor symptoms such as depression, and its safety and tolerability profile. Studies have shown that pramipexole is effective as monotherapy in early Parkinsons disease and as adjunctive therapy in advanced disease. Trials further suggest that the benefits of pramipexole may extend beyond the relief of motor symptoms (akinesia, rigidity and tremor at rest) to the amelioration of depressive symptoms in Parkinsons disease. Pramipexole is generally well tolerated; however, compared with levodopa treatment, pramipexole is associated with a higher rate of some dopaminergic adverse effects.

AB - The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and symptoms of idiopathic Parkinsons disease and for the treatment of moderate-to-severe primary restless legs syndrome. A new extended-release formulation of pramipexole has now also been launched in Europe and the US to improve ease of use, compliance and provide a more continuous therapeutic effect over 24 hours. Before initiating any treatment, the benefit-risk ratio to the individual patient must be considered. For pramipexole in the treatment of Parkinsons disease, this means taking into account the available evidence regarding its symptomatic efficacy, effect on delaying long-term levodopa-related motor complications, beneficial effect on non-motor symptoms such as depression, and its safety and tolerability profile. Studies have shown that pramipexole is effective as monotherapy in early Parkinsons disease and as adjunctive therapy in advanced disease. Trials further suggest that the benefits of pramipexole may extend beyond the relief of motor symptoms (akinesia, rigidity and tremor at rest) to the amelioration of depressive symptoms in Parkinsons disease. Pramipexole is generally well tolerated; however, compared with levodopa treatment, pramipexole is associated with a higher rate of some dopaminergic adverse effects.

KW - Parkinsons-disease, treatment

KW - Pramipexole, pharmacokinetics

KW - Pramipexole, therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=77956672555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956672555&partnerID=8YFLogxK

U2 - 10.2165/11585090-000000000-00000

DO - 10.2165/11585090-000000000-00000

M3 - Article

C2 - 20839895

AN - SCOPUS:77956672555

VL - 24

SP - 829

EP - 841

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 10

ER -